Piper Jaffray analyst Joshua Schimmer calls the Wall Street Journal's report of the New York Attorney General issuing subpoenas to 16 health insurance companies regarding their coverage of Hepatitis C drugs a "refreshing change." The spotlight is finally shifting from the expensive price points of drugs to payors denying coverage, Schimmer tells investors in a research note. Gilead (GILD) has been in focus after the Massachusetts Attorney General suggested the company's drug price has made its Hepatitis C drug inaccessible to consumers, the analyst points out. He believes all parties involved have an "onus to compromise and create a reimbursement system that enables access" while also rewarding drugmakers for their innovations. He reiterates an Overweight rating on Gilead. Representatives from Aetna (AET), CareConnect and EmblemHealth confirmed to the Journal that they received subpoenas. Shares of Gilead, which makes Hepatitis C drug Harvoni, closed yesterday up 21c to $88.80.